Stuart Roberts

In April 2016 Greenland Minerals updated its Feasibility Study on its Kvanefjeld Rare Earths Project in Greenland. Since the original Feasibility Study had been published in May 2015 the price of uranium, a significant by-product at Kvanefjeld, had come down, but Greenland Minerals had also made a lot of progress... Show More

Stuart Roberts

If I said the company name Phosphagenics to you, would it ring a bell? Unless you really know the Life Sciences sector of the ASX really well, probably not. What if I said to you that this was the Melbourne-based company where, in 2013, it was revealed that then CEO... Show More

Stuart Roberts

Pitt Street Research’s bread and butter is issuer-sponsored research of companies that are publicly traded on the ASX. We are big believers in the power of issuer sponsorship to enlarge the pool of quality, widely accessible research on ASX-listed companies, and thereby contribute to the overall efficiency of the Australian... Show More

Stuart Roberts

One of the more impressive re-brandings of a Life Science company that I've seen in recent years is Kazia Therapeutics, formerly Novogen. This company changed its name in late 2017 to reflect the acquisition from Genentech of an impressive new lead compound called GDC-0084, for the treatment of glioblastoma. We... Show More

Stuart Roberts

Every now and then when people ask me about building a portfolio of Life Science companies, I tell them that having a regenerative medicine stock in the portfolio is probably a good idea because we're going into a boom for that field globally. In July last year we at NDF... Show More

Stuart Roberts

Want a sure-fire way to make money in biotech and medical device stocks? There is none. There are, however, certain things you can do to maximise your chances of success. I have been arguing lately that one of the better ways to do that is by buying stock in companies... Show More

Stuart Roberts

In December 2016 NDF Research initiated coverage on Resonance Health (ASX: RHT), a Perth-based company which developed the world’s first non-invasive diagnostic for iron overload, an MRI-based test called FerriScan. This test, which gained both CE Mark and FDA approval in January 2005, has been the basis of a small... Show More

Stuart Roberts

Sometimes it takes a while before good Life Sciences companies make it to being great Life Sciences companies. Phylogica is one such company. I've been following this Perth-based drug discovery operation since its 2005 IPO and I've always been impressed with the quality of the science and of the team,... Show More

No comments.